Approval Alert | Pembrolizumab for Advanced MSI-H/dMMR Endometrial Cancer

In March 2022, the FDA approved pembrolizumab for advanced microsatellite instability–high or mismatch repair–deficient advanced endometrial cancer following prior systemic therapy in any setting.

David M. O’Malley, MD, Talks Next Steps for Treatment in Endometrial Cancer
Video
David M. O’Malley, MD, Talks Next Steps for Treatment in Endometrial Cancer
May 16, 2022 12:00 PM
David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.
David M. O’Malley, MD, Reviews the Benefit of Pembrolizumab for Endometrial Cancer
Video
David M. O’Malley, MD, Reviews the Benefit of Pembrolizumab for Endometrial Cancer
May 6, 2022 6:00 PM
David M. O’Malley, MD, spoke about unmet needs of patients with advanced microsatellite instability–¬high or mismatch repair deficient endometrial carcinoma and the clinical benefit pembrolizumab provides.
David M. O’Malley, MD, Discusses Recent Approval of Pembrolizumab in Endometrial Cancer
Video
David M. O’Malley, MD, Discusses Recent Approval of Pembrolizumab in Endometrial Cancer
Apr 27, 2022 8:00 PM
David M. O’Malley, MD, spoke about the approval of pembrolizumab for patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient.
FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Cancer
Article
FDA Approves Pembrolizumab for Advanced MSI-H/dMMR Endometrial Cancer
Mar 21, 2022 7:09 PM
Pembrolizumab has been approved by the FDA for the use in advanced microsatellite instability–high/mismatch repair–deficient endometrial cancer following prior systemic therapy.